Genmab A/S

Stocks

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 16/06/2026 pm IST			5-day change	1st Jan Change
1,556.00 ^DKK	-2.38%		-3.41%	-23.24%

15/06	Nordic Equities in North America: Ericsson Slides 1.4 Percent	FW
13/06	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI

Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 05/08/2025 at 08:50 pm IST

S&P Capital IQ

GENMAB A/S

-2.38%

Genmab A/S reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was USD 715 million compared to USD 603 million a year ago. Net income was USD 195 million compared to USD 192 million a year ago.

Basic earnings per share from continuing operations was USD 3.06 compared to USD 2.96 a year ago. Diluted earnings per share from continuing operations was USD 3.05 compared to USD 2.94 a year ago.

Latest news about Genmab A/S

15/06	Nordic Equities in North America: Ericsson Slides 1.4 Percent	FW
13/06	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI
11/06	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
11/06	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
10/06	Nordic stocks in North America - Autoliv rose 1.6 percent	FW
09/06	China Approves Pfizer's Tivdak for Cervical Cancer Treatment
09/06	Nordic Equities in North America - AstraZeneca declines 1.8 percent	FW
08/06	Nordic stocks in North America - Ericsson fell 1.8 percent	FW
03/06	Nordic Equities in North America - Ericsson Gains 0.7 Percent	FW
02/06	U.S. Futures Slip, European Stocks Edge Up	DJ
01/06	U.S. Futures Edge Up, European Stocks Mixed	DJ
25/05	Nordic Equities in North America - Astra Zeneca Slips 0.9 Percent	FW
20/05	Nordic Equities in North America - Autoliv Gains 0.9 Percent	FW
18/05	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts	MT
12/05	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW

Chart Genmab A/S

Duration

Period

GMAB: Dynamic Chart

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

3,088

Sector

Biotechnology & Medical Research

Calendar

06/08 - Earnings release - Q2 2026

More about the company